Abivax Stock Nears Key Resistance After Oddo BHF Raises Target by 36%
Abivax climbs 3.41% this Friday to €109.10, driven by a spectacular increase in the price target set by Oddo BHF the previous day. The French biotech company, which has shown an extraordinary stock market performance over the past year, is now approaching a critical technical threshold.
Today's catalyst has been identified: Oddo BHF bank yesterday raised its price target on Abivax from €88 to €120, while issuing an outperform rating. This reevaluation represents an increase of over 36% in the target, translating to a potential upside of about 10% from the current price of €109.10. Abivax's stock now shows a gain of 7.59% over seven days and 10.2% over three months, in a context where the CAC 40 is moderately up by 0.20% at 8,262.65 points. The next market appointment is set for June 1st, when the first quarter 2026 results will be published. In the sector, comparables are also in the green this morning: Sanofi is up 0.41% and UCB is up 0.96%.
Technical Perspective of Today's Session
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
From a technical standpoint, today's session places Abivax in a sensitive zone. The price at €109.10 is very close to the identified resistance at €109.60, a threshold whose breach could pave the way for a new phase of increase. The stock is also trading at the upper end of its Bollinger Bands, at 85% of the spread between the lower bound (€88.31) and the upper bound (€112.77), indicating a potential overbought zone. However, the RSI at 56 remains in neutral territory, without marked bullish excess. The 50-day moving average, located at €100.97, has been significantly exceeded in recent sessions, as has the 200-day moving average at €81.30, confirming a favorable medium-term dynamic. The monthly volatility remains high at 56.24, characteristic of a biotech stock of this profile, while a beta of 0.42 indicates limited sensitivity to overall market movements.
Trésorerie et équivalents de trésorerie de 589,7 millions d'euros au 30/09/2025 ; perte nette de 254,1 millions d'euros sur les neuf mois ; produit net d'ADS d'environ 700,3 millions de dollars (?597,2 M€) en juillet 2025 ; position financière nette de 543,3 millions d'euros ; autonomie financière attendue jusqu'au T4 2027. Hausse significative des dépenses R&D et des charges G&A.
Risks mentioned
Risques inhérents à la recherche et au développement clinique
Risque lié aux décisions des autorités réglementaires (FDA, EMA)
Risque de disponibilité insuffisante de fonds pour couvrir les dépenses d'exploitation futures
Obstacles potentiels au développement clinique et pharmaceutique (données précliniques, CMC, toxicologie, etc.)
Opportunities identified
Avancement des essais de phase 3 d'Obefazimod en rectocolite hémorragique
Présentations 'late-breaking' et résultats favorables communiqués lors de congrès scientifiques
Produit net élevé de l'offre d'ADS prolongeant l'autonomie financière jusqu'au T4 2027
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
